• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

    9/3/25 1:01:32 PM ET
    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMVT alert in real time by email
    • First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patients
    • Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end of the six-month follow-up period
    • Of the 17 responders to therapy, ~50% (8/17) achieved anti-thyroid drug (ATD) free remission at six months following end of batoclimab treatment
    • Two potentially registrational trials for IMVT-1402 in Graves' disease are currently enrolling with topline readouts expected in 2027
    • Roivant to host investor call to discuss these updates today, September 3, 2025, at 4:30 p.m. EDT



    NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Graves' disease (GD) patients treated with batoclimab for 24 weeks, to be presented at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.

    "These novel and encouraging results support FcRn blockade as a potentially effective mechanism for the treatment of Graves' disease, with the six-month remission data providing evidence of potential disease modification," said George Kahaly, M.D., Ph.D., Lead Principal Investigator.

    "We are incredibly excited to present these remission data demonstrating strong durability of response and ATD-free remission in previously uncontrolled patients off-treatment for six months," said Eric Venker, M.D., Pharm.D., CEO of Immunovant. "We believe these data have the potential to be transformative for patients and practice-changing for physicians, if approved by FDA, by addressing a significant unmet need in Graves' disease."

    Graves' Disease Proof-of-Concept Study

    Six-month off-treatment data was generated from a proof-of-concept study of batoclimab in Graves' disease. Batoclimab is Immunovant's first generation fully human monoclonal antibody targeting FcRn. The study included a 24-week treatment period with a dose step-down (Weeks 0-12 at 680 mg weekly (QW) subcutaneously (SC) and Weeks 12-24 at 340 mg QW SC), followed by a 24-week off-treatment follow-up period. The study included patients with active Graves' disease as documented by presence of elevated thyrotropin receptor autoantibodies (TRAb) and hyperthyroid despite ATD therapy. The key endpoint of the study is the proportion of participants who achieve normalization of free triiodothyronine (T3) and free thyroxine (T4) or have T3 / T4 below the lower limit of normal (LLN) at Week 24, without an increase in ATD dose from baseline.

    Graves' Disease Six-month Remission Data

    25 patients were enrolled in the treatment period with 21 patients entering the off-treatment 24-week follow-up period to be assessed for remission:

    • At Week 48, or the end of the six-month follow-up period (patients off-treatment for 24 weeks), ~80% (17/21) patients maintained T3/T4 values ≤ upper limit of normal (ULN), indicating strong durability of response through six months off treatment
    • Of these 17 patients, ~50% (8/17) were in ATD free-remission and an incremental ~30% (5/17) were on ATD doses of 2.5 mg/day following six months off treatment, even with batoclimab's suboptimal step-down dosing design during the treatment period
    • Safety and tolerability were observed to be consistent with prior batoclimab studies



    IMVT-1402 Registrational Trial Design

    Two potentially registrational trials of Immunovant's lead compound IMVT-1402 in Graves' disease will evaluate 600 mg dose for up to 52 weeks without a step-down in dose.

    The two potentially registrational global trials for IMVT-1402 in Graves' disease are currently enrolling with topline readouts expected in 2027.

    Investor Conference Call Information

    Roivant will host a live conference call and webcast at 4:30 p.m. EDT on Wednesday, September 3, 2025, to discuss these Immunovant data. To access the conference call by phone, please register online using this registration link. The presentation and webcast details are available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call.

    About Immunovant, Inc.

    Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

    Forward-Looking Statements

    This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," "may," "might," "will," "would," "should," "expect," "believe," "estimate," "design," "plan," "intend," "anticipate," and other similar expressions are intended to identify forward-looking statements. Such forward looking statements include Immunovant's expectations regarding the clinical and therapeutic benefits of its product candidates, including durability of response, efficacy, tolerability and the potential for disease modification and first-in-class potential; patient enrollment, timing, design, progress, scope and results of its existing and planned clinical trials, including the potential registrational trials for IMVT-1402 in Graves' disease and whether the trial designs will result in improved efficacy data; future development of IMVT-1402 and batoclimab, including the timing and likelihood of expansion into additional indications; the evolution of the treatment paradigm for Graves' disease in North America; the size and growth of the potential markets for Immunovant's product candidates and indication selections, including any estimated market opportunities; expectations regarding the receipt of regulatory approval for its product candidates; and whether, if approved, IMVT-1402 or batcolimab will be successfully distributed, marketed or commercialized. All forward-looking statements are based on estimates and assumptions by Immunovant's management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: initial results or other preliminary analyses or results of early clinical trials may not be predictive of final trial results or of the results of later clinical trials; results of animal studies may not be predictive of results in humans; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant's product candidates, including the timing of the commencement of additional clinical trials; Immunovant's scientific approach, clinical trial design, indication selection, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this presentation; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant's product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the effect of global factors such as geopolitical tensions and adverse macroeconomic conditions on Immunovant's business operations and supply chains, including its clinical development plans and timelines; Immunovant's business is heavily dependent on the successful development, regulatory approval and commercialization of batoclimab and IMVT-1402; Immunovant is in various stages of clinical development for IMVT-1402 and batoclimab; and Immunovant will require additional capital to fund its operations and advance IMVT-1402 and batoclimab through clinical development. These and other risks and uncertainties are more fully described in Immunovant's periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled "Risk Factors" in Immunovant's most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 11, 2025, and Immunovant's subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

    About Roivant

    Roivant (NASDAQ:ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or "Vants" to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit https://roivant.com.

    Roivant Forward-Looking Statements

    This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

    Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.

    Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contacts:

    Investors

    Keyur Parekh

    [email protected]

    Media

    Stephanie Lee

    [email protected]



    Primary Logo

    Get the next $IMVT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMVT
    $ROIV

    CompanyDatePrice TargetRatingAnalyst
    Roivant Sciences Ltd.
    $ROIV
    9/2/2025$16.00Buy
    Citigroup
    Roivant Sciences Ltd.
    $ROIV
    7/10/2025$19.00Buy
    Goldman
    Immunovant Inc.
    $IMVT
    7/10/2025$18.00Neutral
    Goldman
    Immunovant Inc.
    $IMVT
    3/3/2025$20.00Hold
    Jefferies
    Immunovant Inc.
    $IMVT
    1/3/2025Outperform → Peer Perform
    Wolfe Research
    Immunovant Inc.
    $IMVT
    10/10/2024$36.00Outperform
    Raymond James
    Immunovant Inc.
    $IMVT
    10/9/2024$47.00 → $53.00Outperform
    Oppenheimer
    Immunovant Inc.
    $IMVT
    3/28/2024$50.00Outperform
    Oppenheimer
    More analyst ratings

    $IMVT
    $ROIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Roivant Sciences with a new price target

    Citigroup initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $16.00

    9/2/25 8:40:38 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Roivant Sciences with a new price target

    Goldman resumed coverage of Roivant Sciences with a rating of Buy and set a new price target of $19.00

    7/10/25 9:00:08 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Immunovant Sciences with a new price target

    Goldman resumed coverage of Immunovant Sciences with a rating of Neutral and set a new price target of $18.00

    7/10/25 8:56:07 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMVT
    $ROIV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $IMVT
    $ROIV
    SEC Filings

    View All

    $IMVT
    $ROIV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $IMVT
    $ROIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    1/15/25 4:36:38 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roivant Sciences Ltd. was granted 4,473,684 shares and bought $58,000,008 worth of shares (1,526,316 units at $38.00), increasing direct ownership by 8% to 79,805,331 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    10/4/23 5:15:20 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roivant Sciences Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Roivant Sciences Ltd. (0001635088) (Filer)

    9/3/25 1:38:54 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunovant Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Immunovant, Inc. (0001764013) (Filer)

    9/3/25 1:09:06 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunovant Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Immunovant, Inc. (0001764013) (Filer)

    8/28/25 4:13:38 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

    Orphan drug designation from Japan's Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternativeA global Phase 2 PHocus study of mosliciguat in PH-ILD is currently ongoing and will be highlighted in a study-in-progress poster at the European Respiratory Society International Congress 2025 on September 28th WALTHAM, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (NASDAQ:ROIV) company, today announced th

    9/4/25 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

    First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end of the six-month follow-up periodOf the 17 responders to therapy, ~50% (8/17) achieved anti-thyroid drug (ATD) free remission at six months following end of batoclimab treatmentTwo potentially registrational trials for IMVT-1402 in Graves' disease are currently enrolling with topline readouts expected in 2027Roivant to host investor call to discuss these updates today, September 3, 2025, at 4:30 p.m. E

    9/3/25 1:01:32 PM ET
    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

    First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end of the six-month follow-up periodOf the 17 responders to therapy, ~50% (8/17) achieved anti-thyroid drug (ATD) free remission at six months following end of batoclimab treatmentTwo potentially registrational trials for IMVT-1402 in Graves' disease are currently enrolling with topline readouts expected in 2027Roivant to host investor call to discuss these updates today, September 3, 2025, at 4:30 p.m. E

    9/3/25 12:57:50 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Ramaswamy Vivek sold $22,456,210 worth of shares (1,775,749 units at $12.65), decreasing direct ownership by 5% to 35,508,359 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    9/5/25 5:01:38 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Pulik Richard covered exercise/tax liability with 2,340 shares, decreasing direct ownership by 0.59% to 393,978 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    9/2/25 9:00:09 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Pulik Richard covered exercise/tax liability with 1,235 shares, decreasing direct ownership by 0.31% to 396,318 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    8/22/25 9:00:45 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMVT
    $ROIV
    Leadership Updates

    Live Leadership Updates

    View All

    Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

    Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin

    9/23/24 8:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

    NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

    3/26/24 6:22:00 PM ET
    $PGTI
    $ROIV
    $RUN
    Building Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

    BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

    11/10/23 8:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMVT
    $ROIV
    Financials

    Live finance-specific insights

    View All

    $IMVT
    $ROIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

    First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end of the six-month follow-up periodOf the 17 responders to therapy, ~50% (8/17) achieved anti-thyroid drug (ATD) free remission at six months following end of batoclimab treatmentTwo potentially registrational trials for IMVT-1402 in Graves' disease are currently enrolling with topline readouts expected in 2027Roivant to host investor call to discuss these updates today, September 3, 2025, at 4:30 p.m. E

    9/3/25 1:01:32 PM ET
    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

    First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end of the six-month follow-up periodOf the 17 responders to therapy, ~50% (8/17) achieved anti-thyroid drug (ATD) free remission at six months following end of batoclimab treatmentTwo potentially registrational trials for IMVT-1402 in Graves' disease are currently enrolling with topline readouts expected in 2027Roivant to host investor call to discuss these updates today, September 3, 2025, at 4:30 p.m. E

    9/3/25 12:57:50 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

    Initiated a second potentially registrational study of IMVT-1402 in Graves' disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren's disease (SjD), both in June 2025All other clinical trials in previously announced six-indications remain on track with increased focus on clinical executionRemission data from the batoclimab proof-of-concept study in GD to be reported at the American Thyroid Association (ATA) Annual Meeting in September 2025Current cash balance provides runway for announced indications through GD readout expected in 2027 NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling n

    8/11/25 7:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/12/24 4:58:58 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Roivant Sciences Ltd.

    SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)

    11/12/24 10:34:18 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care